All In Biotech

BLA 125360 · Merz Pharms

Xeomin

Incobotulinumtoxina · Injection · Acetylcholine Release Inhibitor; Neuromuscular Blocker

Novel

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jul 30, 2010

Approved uses

10

Original approval plus efficacy supplements

Registered trials

183

57 Phase 3, 17 recruiting

FAERS reports

5,818

787 serious, 110 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including lower limb spasticity in...

What it is approved for

From the label in effect Jul 10, 2026.

XEOMIN is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment or improvement of: Chronic sialorrhea in patients 2 years of age and older ( 1.1 ) Upper limb spasticity in patients 2 years of age and older ( 1.2 ) Cervical dystonia in adults ( 1.3 ) Blepharospasm in adults ( 1.4 ) the appearance of upper facial lines in adults: moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity ( 1.5 ) moderate to severe horizontal forehead lines associated with frontalis muscle activity ( 1.5 ) moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity ( 1.5 ) 1.1 Chronic Sialorrhea XEOMIN is indicated for the treatment of chronic sialorrhea in patients 2 years of age and older. 1.2 Upper Limb Spasticity XEOMIN is indicated for the treatment of upper limb spasticity in patients 2 years of age and older. 1.3 Cervical Dystonia XEOMIN is indicated for the treatment of cervical dystonia in adult patients. 1.4 Blepharospasm XEOMIN is indicated for the treatment of blepharospasm in adult patients. 1.5 Upper Facial Lines (Glabellar Lines, Horizontal Forehead Lines, and Lateral Canthal Lines) XEOMIN is indicated in adult patients for the temporary improvement in the appearance of upper facial lines: moderate to severe glabellar lines (GL) associated with corrugator and/or procerus muscle activity moderate to severe horizontal forehead lines (HFL) associated with frontalis muscle activity moderate to severe lateral canthal lines (LCL) associated with orbicularis oculi muscle activity.

Mechanism: XEOMIN blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of SNAP25, a presynaptic target protein essential for the release of acetylcholine. In both muscles and glands, impulse...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 25, 2026 Supplement 108 · Efficacy LetterLabel
  • Jul 5, 2024 Supplement 99 · Efficacy
  • Dec 18, 2020 Supplement 86 · Efficacy · priority review LabelLetter
  • Aug 18, 2020 Supplement 78 · Efficacy LetterLabel
  • May 10, 2019 Supplement 74 · Efficacy LetterLabel
  • Jul 3, 2018 Supplement 73 · Efficacy · priority review LabelLetter
  • Dec 22, 2015 Supplement 67 · Efficacy LabelLetter
  • Jul 20, 2011 Supplement 7 · Efficacy Label
  • Jul 30, 2010 Supplement 1 · Efficacy LabelLetter
  • Jul 30, 2010 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
3 products under this application
  • Xeomin · incobotulinumtoxinA 200 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
  • Xeomin · incobotulinumtoxinA 50 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
  • Xeomin · incobotulinumtoxinA 100 UNITS/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Incobotulinumtoxina" as an intervention, any sponsor and status, largest first.

All 183 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,876
  • off label use1,218
  • therapeutic response decreased761
  • injection site pain343
  • overdose237
  • product preparation issue216
  • injection site swelling213
  • headache195
  • product use in unapproved indication195
  • pain181
  • injection site erythema140
  • eyelid ptosis134

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20082
201116
201266
201316
201420
2015174
2016354
2017242
2018368
2019315
2020394
2021542
2022555
2023651
2024830
2025754
2026519

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xeomin (Incobotulinumtoxina)

2024 spending

$3.6M

Beneficiaries

1,293

3,207 claims

Per beneficiary

$2,815

$602.51 per unit

View as table
YearSpending
2020$1,004,156
2021$1,282,706
2022$2,236,227
2023$2,996,460
2024$3,639,657

Part B: Xeomin (Incobotulinumtoxina) · HCPCS J0588

2024 spending

$28.6M

Beneficiaries

12,164

29,626 claims

Per beneficiary

$2,355

2024 ASP limit $5.23 per unit

View as table
YearSpending
2020$17,986,978
2021$19,592,905
2022$21,780,968
2023$25,678,441
2024$28,640,185

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 123 on PubMed

Sponsor: Merz Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.